

A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

NCT06734351

Status	RECRUITING
Phase	Phase 3
Sponsor	AbbVie
Enrollment	231 participants

Key Eligibility Criteria

Inclusion (2)

- Has moderate (3), significant (4), or severe (5) mid-face volume deficit on the 5-point photonumeric MFVDS based on evaluating investigator's (EI) live assessment.
- Mid-face is amenable to achieving at least a 1-point improvement in MFVDS score with the allowed injection volume in the treating investigator's (TI) judgement.

Exclusion (3)

- Significant skin laxity in the midface in the opinion of the TI.
- Significant skin pigmentation disorders or discoloration in the mid-face area that would interfere with the visual assessment of the mid-face area.
- Current cutaneous inflammatory or infectious processes (e.g., acne, herpes), abscess, unhealed wound, or cancerous or precancerous lesion on the face.

Locations (9 total)

Total Skin and Beauty Dermatology Center /ID# 258164, Birmingham, Alabama, United States
Advanced Research Associates - Glendale /ID# 276812, Glendale, Arizona, United States
Susan H. Weinkle MD /ID# 258160, Bradenton, Florida, United States
... and 6 more locations